Current Report Filing (8-k)
March 04 2020 - 9:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2020
MODERNA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38753
|
|
81-3467528
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
200 Technology Square
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip code)
|
(Registrants telephone number, including area code): (617)
714-6500
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.0001 per share
|
|
MRNA
|
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01.
|
Regulation FD Disclosure.
|
On March 4, 2020, Moderna, Inc. (the Company) provided an update regarding its participation in the creation of a potential vaccine to respond to
the current public health threat of the coronavirus labeled SARS-CoV-2. The Company confirmed that the U.S. Food and Drug Administration has completed its review of the Investigational New Drug application for mRNA-1273, the Companys potential
vaccine for SARS-CoV-2, and allowed it to proceed to the clinic (as announced on March 3, 2020 by Health and Human Services Secretary Alex Azar). On February 24, 2020, the first clinical batch of mRNA-1273 was shipped to and received by the NIH for
use in the Phase 1 clinical trial.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 4, 2020
|
|
|
|
MODERNA, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Lori Henderson
|
|
|
|
|
|
|
Lori Henderson
|
|
|
|
|
|
|
General Counsel and Secretary
|
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024